Deals of the year 2009: M&A – Pfizer prepares for life after Lipitor
Euromoney, is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024
Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
CAPITAL MARKETS

Deals of the year 2009: M&A – Pfizer prepares for life after Lipitor

A big M&A deal was a no-brainer, but the Wyeth buyout was still a surprise.

Transaction value: $68.4 billion
Date: Announced January 2009, completed October 2009
Advisers to Pfizer: Bank of America Merrill Lynch, Goldman Sachs, JPMorgan, Barclays Capital, Citi
Advisers to Wyeth: Evercore, Morgan Stanley
Global coordinators: Goldman Sachs, HSBC, JPMorgan

Although secondary financial markets recovered strongly last year and primary debt and equity capital markets bankers were all kept busy, the shattered confidence of corporate management teams and investors was most evident in the collapse of M&A volume. Global volume totalled $2.4 trillion in 2009, the lowest since 2004 and down 24% on the $3.17 trillion announced in 2008, according to Dealogic. Financial sponsor activity fell sharply: buyouts totalled $75.9 billion in 2009, the lowest volume since 2001, down from $191.8 billion in 2008.

Gift this article